Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Biomarker-Guided Feasibility/Efficacy Trial of Ruxolitinib in Patients With High-Risk of Chronic Graft-Versus-Host Disease Development After Allogeneic Hematopoietic Cell Transplantation

NCT07025538 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT07025538
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07025538 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Biomarker-Guided Feasibility/Efficacy Trial of Ruxolitinib in Patients With High-Risk of Chronic Graft-Versus-Host Disease Development After Allogeneic Hematopoietic Cell Transplantation
Lead sponsor
City of Hope Medical Center
Phase
Phase 1
Overall status
Recruiting
Start date
April 29, 2026
Completion date
June 22, 2028
Enrollment
42 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hematopoietic and lymphatic system neoplasm